A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (CIRRUS)

A 4 Week, Double Blind, Placebo Controlled, Randomised, Parallel Group, Multicentre, Phase IIa Study to Investigate the Safety and Tolerability of AZD5069 as Oral Capsules in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

The purpose of this study is the evaluate the safety and tolerability of AZD5069 in patients with Chronic Obstructive Pulmonary Disease

Study Overview

• Status: Completed
• Conditions: Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD); Laymen Terminology Chronic Bronchitis and Emphysema
• Intervention / Treatment: Drug: Placebo; Drug: AZD5069 50mg; Drug: AZD5069 80mg

• Study Type: Interventional
• Enrollment (Actual): 109
• Phase: Phase 2

Contacts and Locations

Study Locations

• Bulgaria
  • Sofia, Bulgaria
    • Research Site
• Germany
  • Berlin, Germany
    • Research Site
  • GROßHANSDORF, Germany
    • Research Site
• Hungary
  • Debrecen, Hungary
    • Research Site
  • Pécs, Hungary
    • Research Site
  • Szeged, Hungary
    • Research Site
  • Százhalombatta, Hungary
    • Research Site
• Ukraine
  • Kyiv, Ukraine
    • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Clinical diagnosis of COPD with symptoms for more than one year before screening
• Body mass index of 18-30 kg/m2 and weight of 50-100kg
• Current or ex-smokers with a smoking history of at least 10 pack years (1 pack year = tobacco consumption corresponding to 20 cigarettes smoked per day for one year) at screening
• FEV1 of 30% or above and less than 80% of the predicted normal value post-bronchodilator at screening
• FEV1/FVC less than 70% post-bronchodilator at screening

Exclusion Criteria:

• Any clinically significant disease or disorder
• Exacerbation of COPD which was not resolved within 30 days of first dosing
• Patients who have received live or live-attenuated vaccine in the 2 weeks prior to first dosing
• Asthma and any current respiratory tract disorder other than COPD which is considered to be clinically significant
• Disease history suggesting reduced or abnormal immune function other than that related to COPD

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: 1; Placebo dose	Drug: Placebo; Oral dose bid
Experimental: 2; Treatment arm AZD5069 50mg	Drug: AZD5069 50mg; Oral dose bid
Experimental: 3; Treatment arm AZD5069 80mg	Drug: AZD5069 80mg; Oral dose bid

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patients Who Experienced at Least One Adverse Events(s)	Adverse event (AE) data, both serious and non-serious. An AE is the development of an undesirable medical condition (eg, nausea, chest pain, tachycardia, laboratory findings) or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product.	From start of treatment (Day 0) up to 28 days (End of Treatment)
Number of Participants With Abnormal Physical Examination Findings	Physical examination includes assessment of general appearance, skin, head and neck (including ears, eyes, nose and throat), lymph nodes, musculo-skeletal (including spine and extremities), cardiovascular, lungs and abdomen. The findings were deemed to be normal/abnormal based on the clinical judgment of the investigator.	Last Observation on Treatment (up to Day 28)
Number of Participants With Abnormal Electrocardiogram (ECG)	ECGs were recorded in the supine position after the patient has rested for 10 minutes. Heart rate, QRS duration, PR, RR and QT intervals were recorded. Overall evaluation of the ECG is classified as normal, abnormal or borderline. Only participants with ECG at baseline classified as normal are reported (ie, only changes from normal to abnormal).	Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)
Change From Baseline to End of Treatment for Leucocytes Count in Blood (Safety Blood Sample)	The change in circulating leucocyte counts (including neutrophils) is calculated as the End of Treatment value minus the Baseline value.	Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)
Change From Baseline to End of Treatment for Body Temperature	The change in body temperature (oral) is calculated as the End of Treatment value minus the Baseline value.	Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)
Change From Baseline to End of Treatment for Systolic Blood Preassure (Vital Signs)	The change in systolic blood pressure (Vital Sign) is calculated as the End of Treatment value minus the Baseline value.	Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)
Change From Baseline to End of Treatment for Diastolic Blood Pressure (Vital Signs)	The change in diastolic blood pressure (Vital Sign) is calculated as the End of Treatment value minus the Baseline value.	Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)
Change From Baseline to End of Treatment for Pulse Rate (Vital Signs)	The change in pulse rate (Vital Sign) is calculated as the End of Treatment value minus the Baseline value.	Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)
Change From Baseline to End of Treatment for FEV1 Pre-bronchodilator (Lung Function Test)	The change in FEV1 Pre-bronchodilator is calculated as the End of Treatment value minus the Baseline value.	Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)
Change From Baseline to End of Treatment for FEV1 Post-bronchodilator (Lung Function Test)	The change in FEV1 Post-bronchodilator is calculated as the End of Treatment value minus the Baseline value.	Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)
Number of Participants Who Developed High Transaminase Values (Clinical Chemistry)	High Transaminase Values are defined as a measurment of ALT (alanine aminotransferase) or AST (aspartate aminotransferase) greater than or equal to 3 times the upper limit of normal (ALT ULN = 36 IU/L, AST ULN = 33 IU/L).	Up to Follow-up Visit (3 to 18 days after End of Treatment [Day 28])
Change From Baseline to End of Treatment for Total Protein (Urinalysis)	The change in total protein in urine is calculated as the End of Treatment value minus the Baseline value.	Baseline (last non-missing assessment prior to first dose of study medication) and End of Treatment (Day 28)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Plasma Concentration of AZD5069 After 1 Hour of Dosing	At this visit, approximately 1 hour after dosing (at the clinic), a blood sample was collected for determination of drug concentration in plasma.	End of Treatment (Day 28), 1 hour after dosing
Area Under the Plasma Concentration Curve of AZD5069	The area under the plasma concentration curve is estimated from time 0 (dosing) to 24 hours after dosing.	End of Treatment (Day 28); pre-dose, 1, 2, 3, and 5 hours after dosing
Maximum Plasma Concentration for AZD5069	The maximum plasma concentration (Cmax) is the highest level of drug in plasma.	End of Treatment (Day 28); pre-dose, 1, 2, 3, and 5 hours after dosing
Time to Maximum Plasma Concentration for AZD5069	Time (in relation to dosing) at which the maximum plasma concentration is observed.	End of Treatment (Day 28); pre-dose, 1, 2, 3, and 5 hours after dosing
Maximum Reduction of Circulating Neutrophils in Blood, From Baseline	The change in circulating neutrophils in blood is calculated as the visit value minus the Baseline value. Only participants with reduction are considered.	Baseline (last non-missing assessment prior to first dose of study medication), weeks 1, 2 and 3, and End of Treatment (Day 28)

Collaborators and Investigators

• Sponsor: AstraZeneca

Publications and helpful links

General Publications

• Kirsten AM, Forster K, Radeczky E, Linnhoff A, Balint B, Watz H, Wray H, Salkeld L, Cullberg M, Larsson B. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD. Pulm Pharmacol Ther. 2015 Apr;31:36-41. doi: 10.1016/j.pupt.2015.02.001. Epub 2015 Feb 11.

Helpful Links

• D3550C00002_Revised_Clinical_Study_Protocol.pdf
• D3550C00002_Study_Synopsis.pdf

Study record dates

Study Major Dates

• Study Start: November 1, 2010
• Primary Completion (Actual): March 1, 2011
• Study Completion (Actual): March 1, 2011

Study Registration Dates

• First Submitted: November 2, 2010
• First Submitted That Met QC Criteria: November 2, 2010
• First Posted (Estimate): November 3, 2010

Study Record Updates

• Last Update Posted (Estimate): September 17, 2015
• Last Update Submitted That Met QC Criteria: August 27, 2015
• Last Verified: August 1, 2015

More Information

Terms related to this study

• Keywords: Chronic Obstructive Pulmonary Disease, Neutrophil, Respiratory Disease
• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Bronchial Diseases; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive; Emphysema; Bronchitis; Bronchitis, Chronic
• Other Study ID Numbers: D3550C00002; 2010-021217-23 (EudraCT Number)